Pan Edward, Tsai Jerry S, Mitchell Susan B
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Anticancer Res. 2009 Oct;29(10):4309-13.
Venous thromboembolism (VTE) is a common complication in glioblastoma (GB) patients.
A retrospective medical record review identified 294 GB patients with VTE or ICH; 146 patients with sufficient treatment records were included. Treatment approaches for GB patients who developed VTE were also reported.
Of 146 patients, 41 (28%) developed VTE and 3 (2%) developed ICH. Seven (17%) of the 41 VTE patients developed recurrent VTE. Practice patterns for VTE treatment varied widely. Patient demographics were not significantly associated with VTE development.
Despite a low incidence of ICH, even with anticoagulation therapy, physicians are reluctant to administer anticoagulants to GB patients with VTE. The optimum treatment for GB patients with VTE has not been established; however, the benefits of anticoagulation therapy may outweigh the risks of ICH. A prospective clinical trial to evaluate the potential benefits for deep venous thrombosis prophylaxis in GB patients is warranted.
静脉血栓栓塞症（VTE）是胶质母细胞瘤（GB）患者常见的并发症。
通过回顾性病历审查确定了294例发生VTE或脑出血（ICH）的GB患者；纳入了146例有充分治疗记录的患者。还报告了发生VTE的GB患者的治疗方法。
146例患者中，41例（28%）发生VTE，3例（2%）发生ICH。41例VTE患者中有7例（17%）发生复发性VTE。VTE治疗的实践模式差异很大。患者人口统计学特征与VTE发生无显著相关性。
尽管ICH发生率较低，即使采用抗凝治疗，医生也不愿对发生VTE的GB患者使用抗凝剂。GB合并VTE患者的最佳治疗方案尚未确定；然而，抗凝治疗的益处可能超过ICH的风险。有必要进行一项前瞻性临床试验，以评估GB患者预防深静脉血栓形成的潜在益处。
